Netarsudil
Sign in to save this workspacePrimary targets: ROCK1, ROCK2 · FDA status: FDA Approved
Selectivity scorecard
KISS
93.22
Gini
0.676
CATDS
0.012
Computed from wild-type kinome inhibition at 1 μM. Gini reproduces the published values within tolerance; KISS and CATDS are computed but pending reconciliation with the paper's reference code.
Polypharmacology radar
Top 20 strongest-inhibited wild-type kinases for Netarsudil. Strongest target: P70S6K_RPS6KB1 at 99.7% inhibition.
Accessible data table
| Rank | Target | Inhibition % | Residual activity % |
|---|---|---|---|
| 1 | P70S6K_RPS6KB1 | 99.7% | 0.3% |
| 2 | PKCD | 99.4% | 0.6% |
| 3 | ROCK1 | 99.3% | 0.7% |
| 4 | MSK2_RPS6KA4 | 99.1% | 0.9% |
| 5 | PRKX | 98.3% | 1.7% |
| 6 | P70S6KB_RPS6KB2 | 98.2% | 1.8% |
| 7 | PKG1A | 97.3% | 2.7% |
| 8 | PKCEPSILON | 97.3% | 2.7% |
| 9 | PKACB | 97.2% | 2.8% |
| 10 | MSK1_RPS6KA5 | 97.1% | 2.9% |
| 11 | PKCETA | 97.0% | 3.0% |
| 12 | PKA | 96.6% | 3.4% |
| 13 | RSK3 | 96.6% | 3.4% |
| 14 | ROCK2 | 96.0% | 4.0% |
| 15 | STK38_NDR1 | 95.8% | 4.2% |
| 16 | PKG2_PRKG2 | 95.7% | 4.3% |
| 17 | PKACG | 95.4% | 4.6% |
| 18 | STK38L_NDR2 | 95.0% | 5.0% |
| 19 | DMPK2 | 94.8% | 5.2% |
| 20 | PKD2_PRKD2 | 94.6% | 5.4% |
Selectivity landscape
Where Netarsudil sits in the 92-drug selectivity landscape (KISS vs Gini). The highlighted point is Netarsudil.
Atlas insights for Netarsudil
Pathway-space view of what this drug actually does, drawn from the Pathway Atlas.
On-target vs off-target shadow
On-target0%
Off-target100%
Ghost (2nd-order)0%
| Pathway | Composition | Total |Π| |
|---|---|---|
| ADIPOGENESIS | 1866.69 | |
| ALLOGRAFT_REJECTION | 2431.01 | |
| ANDROGEN_RESPONSE | 1289.93 | |
| ANGIOGENESIS | 732.85 | |
| APICAL_JUNCTION | 4394.71 | |
| APICAL_SURFACE | 523.79 | |
| APOPTOSIS | 4737.24 | |
| BILE_ACID_METABOLISM | 615.06 | |
| CHOLESTEROL_HOMEOSTASIS | 490.11 | |
| COAGULATION | 922.66 | |
| COMPLEMENT | 2337.62 | |
| DNA_REPAIR | 888.50 | |
| E2F_TARGETS | 3736.15 | |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 1519.62 | |
| ESTROGEN_RESPONSE_EARLY | 1834.59 | |
| ESTROGEN_RESPONSE_LATE | 1881.63 | |
| FATTY_ACID_METABOLISM | 312.35 | |
| G2M_CHECKPOINT | 3976.82 | |
| GLYCOLYSIS | 1928.79 | |
| HEDGEHOG_SIGNALING | 690.96 | |
| HEME_METABOLISM | 2180.93 | |
| HYPOXIA | 3216.89 | |
| IL2_STAT5_SIGNALING | 1660.64 | |
| IL6_JAK_STAT3_SIGNALING | 1593.32 | |
| INFLAMMATORY_RESPONSE | 2482.81 | |
| INTERFERON_ALPHA_RESPONSE | 331.98 | |
| INTERFERON_GAMMA_RESPONSE | 2274.05 | |
| KRAS_SIGNALING_DN | 619.71 | |
| KRAS_SIGNALING_UP | 1616.26 | |
| MITOTIC_SPINDLE | 3640.10 | |
| MTORC1_SIGNALING | 2333.41 | |
| MYC_TARGETS_V1 | 2386.53 | |
| MYC_TARGETS_V2 | 643.13 | |
| MYOGENESIS | 2986.67 | |
| NOTCH_SIGNALING | 264.75 | |
| OXIDATIVE_PHOSPHORYLATION | 903.37 | |
| P53_PATHWAY | 2733.41 | |
| PANCREAS_BETA_CELLS | 571.98 | |
| PEROXISOME | 647.91 | |
| PI3K_AKT_MTOR_SIGNALING | 5465.69 | |
| PROTEIN_SECRETION | 1228.19 | |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 131.66 | |
| SPERMATOGENESIS | 1582.74 | |
| TGF_BETA_SIGNALING | 1481.12 | |
| TNFA_SIGNALING_VIA_NFKB | 3072.35 | |
| UNFOLDED_PROTEIN_RESPONSE | 1022.34 | |
| UV_RESPONSE_DN | 2630.84 | |
| UV_RESPONSE_UP | 1833.44 | |
| WNT_BETA_CATENIN_SIGNALING | 1063.64 | |
| XENOBIOTIC_METABOLISM | 1151.73 |
Anti-tumor matches — the "ideal patient" search
| Sample | Cancer type | cos to ideal |
|---|---|---|
| EPT0291 | EPN | 0.839 |
| TCGA-CF-A5U8-01A-11R-A28M-07 | — | 0.831 |
| SRR23303752 | — | 0.826 |
| b6a7e87e-2674-4a48-a3c2-c8a9806762b5 | — | 0.822 |
| R247 | — | 0.818 |
Annotations
Sign in to read and post annotations.
Loading…